Biodesix enters $50M common stock purchase agreement with Lincoln Park Capital

BIODESIX INC

Up to $50M of common stock may be sold to Lincoln Park over 36 months at Biodesix's discretion.
Purchase price based on prevailing market prices with no upper limit per share.
No warrants, derivatives, financial or business covenants; LPC cannot short or hedge.
Biodesix issued commitment shares as a fee and can terminate the agreement at any time without cost.
Net proceeds to be used for growth strategy and general corporate purposes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.